Supplementary Figure S2 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

作者：Darren Cowzer, Henry S. Walch, Pranita Atri, Farheen Shah, Risha Huq, Rohit Thummalapalli, Fatema Nagib, Anna M. Varghese, Danny N. Khalil, Wungki Park, Benoı̂t Rousseau, Andrea Cercek, Joseph Patrick Erinjeri, Randy Yeh, Richard Kinh Gian, Olca Baştürk, Jinru Shia, Debyani Chakravarty, Michael F. Berger, Nikolaus D. Schultz, Mithat Gönen, Eileen Mary O'Reilly, William R. Jarnagin, Ghassan K. Abou‐Alfa, David B. Solit, Walid Khaled Chatila, James J. Harding · 年份：2026 · DOI：10.1158/1078-0432.33776369 · 研究领域：Medicine、Internal medicine、Oncology、Gastroenterology、Cancer research

Supplemental Figure 2: A. Comparison of gene-level alterations showing significant differences across BTC subtypes. B. Comparison of oncogenic signaling pathway alterations across BTC subtypes. C. Comparison of gene-level alteration between different age groups divided into decades. D. Percentage of samples with clonal, subclonal, and indeterminate mutations broken down by subtype. Proportion of clonal, subclonal, and indeterminate mutations broken down by subtypes. E. Oncoprint comparing the tumors with subclonal ERBB2 mutations to those with clonal mutations. F. Comparison of actionability in 2017 and 2023 across subtypes. G. Percentage of patients getting targeted therapy over the years, with drug approvals plotted below. Fifteen patients who received HAI treatment only, as well as 1 patient treated outside of MSK, were excluded from the plot.